Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMDP) Change in Account Payables (2021 - 2025)

Historic Change in Account Payables for LifeMD (LFMDP) over the last 5 years, with Q3 2025 value amounting to -$4.7 million.

  • LifeMD's Change in Account Payables fell 68083.89% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 4081.51%. This contributed to the annual value of $4.9 million for FY2024, which is 40350.89% up from last year.
  • As of Q3 2025, LifeMD's Change in Account Payables stood at -$4.7 million, which was down 68083.89% from $8.6 million recorded in Q2 2025.
  • LifeMD's Change in Account Payables' 5-year high stood at $8.6 million during Q2 2025, with a 5-year trough of -$4.7 million in Q3 2025.
  • For the 5-year period, LifeMD's Change in Account Payables averaged around $530451.2, with its median value being $259180.0 (2022).
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 188780.9% in 2022, then plummeted by 68083.89% in 2025.
  • Quarter analysis of 5 years shows LifeMD's Change in Account Payables stood at -$2.4 million in 2021, then soared by 76.07% to -$576066.0 in 2022, then surged by 351.27% to $1.4 million in 2023, then crashed by 90.19% to $142015.0 in 2024, then tumbled by 3436.36% to -$4.7 million in 2025.
  • Its last three reported values are -$4.7 million in Q3 2025, $8.6 million for Q2 2025, and -$330456.0 during Q1 2025.